Outset Medical, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Outset Medical develops and commercializes the Tablo Hemodialysis System, an FDA-cleared dialysis platform designed for hospital, clinic, and home use. Tablo integrates water purification, dialysate production, connectivity, and data analytics in a compact console. The filing covers the unaudited three months ended March 31, 2022, compared with the three months ended March 31, 2021.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $30.6 million | $22.9 million | Up 33% |
| Product revenue | $25.7 million | $18.2 million | Up 41% |
| Service and other revenue | $4.9 million | $4.7 million | Up 4% |
| Gross profit | $4.4 million | $0.3 million | Up $4.2 million |
| Gross margin | 14.5% | 1.3% | Up 13.2 percentage points |
| Operating loss | $36.5 million | $29.7 million | Loss increased $6.8 million |
| Net loss | $36.9 million | $30.0 million | Loss increased $6.9 million |
| Net loss per share | $0.78 | $0.70 | Loss per share increased |
| Net cash used in operating activities | $38.3 million | $38.6 million | Improved $0.3 million |
Product revenue growth reflected a $3.3 million increase in console revenue and a $4.2 million increase in consumables revenue. Console growth was attributed to new customer adoption and fleet expansion; consumables growth reflected a larger installed base and higher average selling prices.
Operating expenses were $40.9 million, up 37% year over year. Research and development increased 43% to $10.8 million, sales and marketing increased 55% to $20.4 million, and general and administrative expense increased 5% to $9.7 million. Stock-based compensation was $5.0 million.
At March 31, 2022, cash and cash equivalents were $114.3 million, short-term investments were $187.9 million, and restricted cash was $33.3 million. Total cash, cash equivalents, short-term investments, and restricted cash were $335.6 million. Total assets were $431.7 million and total stockholders’ equity was $345.5 million.
Debt consisted primarily of a $30.0 million senior secured term loan, reported at $29.8 million net of discount. The loan bears interest at the greater of 0.5% above the Wall Street Journal prime rate or 3.75%; the stated rate was 4.00% at March 31, 2022. Interest-only payments continue through May 2023, followed by monthly principal and interest payments through maturity on November 1, 2025. The company must maintain restricted cash at least equal to the outstanding principal balance.
Material changes versus the prior comparable period
- Revenue increased 33%, driven primarily by higher console and consumables sales.
- Gross margin improved substantially to 14.5%, primarily due to cost-reduction activities, including internal console manufacturing, additional cartridge sourcing, and manufacturing scale initiatives.
- Operating expenses grew faster than revenue, particularly sales and marketing and research and development, resulting in a larger operating and net loss.
- Cash used in investing activities increased to $33.4 million from $6.8 million, primarily because of $64.7 million of investment-security purchases and $1.5 million of capital expenditures.
- Cash, cash equivalents, and restricted cash declined by $68.0 million during the quarter, compared with a $43.2 million decline in Q1 2021. The decline was partly offset by $3.7 million of proceeds from stock-option exercises and employee stock purchases.
- Inventories increased to $42.9 million from $39.2 million at December 31, 2021, reflecting advance purchases and efforts to mitigate supply-chain disruptions.
Outlook, management commentary, risks, and unusual items
Management expects significant expenses and operating losses to continue while investing in commercial expansion, product development, and infrastructure. Management believes existing cash, investments, and cash generated from sales will fund anticipated needs for at least the next 12 months from the filing date.
Management’s strategy is to expand Tablo adoption in acute-care settings, increase utilization and fleet expansion with existing customers, and develop the home dialysis market. As of March 31, 2022, the company had 38 capital sales team members, 96 clinical sales team members, and 108 field-service team members.
Supply-chain constraints, freight-cost inflation, component shortages, longer lead times, and transportation challenges—particularly for cartridges produced in Southeast Asia—could limit product availability and pressure margins. The company qualified a second cartridge source in Mexico, but does not assure that disruptions will be eliminated.
COVID-19-related disruptions, healthcare labor shortages, inflation, geopolitical instability including the Russia-Ukraine conflict, interest-rate and foreign-exchange changes, and reduced customer capital spending may adversely affect demand, costs, and operations. The company also faces substantially larger competitors, including Fresenius, Baxter, B. Braun, and Quanta.
No material litigation was reported. The company reported no off-balance-sheet arrangements and no material changes to contractual obligations from the 2021 Form 10-K. Unrealized losses on available-for-sale securities were $0.5 million in other comprehensive loss; no other-than-temporary impairment was recognized.
Important facts for investors to verify
- Whether revenue growth and consumables utilization continue to offset elevated sales, marketing, research, and infrastructure spending.
- Whether gross-margin improvement is sustained after considering freight, component, manufacturing, warranty, and service costs.
- The pace of cash burn and whether additional equity or debt financing will be required before the company reaches profitability.
- Execution of the Mexico cartridge-sourcing initiative and the effect of supply-chain conditions on product availability and margins.
- Progress in home-dialysis adoption, including the performance conditions tied to home patients under executive performance stock units.
- Compliance with the term-loan covenants, including the requirement to maintain restricted cash equal to outstanding principal.
- Competitive, regulatory, reimbursement, customer staffing, and healthcare-market risks affecting Tablo adoption.